Accure Therapeutics is a pharmaceutical R&D company focused on developing treatments for central nervous system (CNS) disorders, utilizing a distinct approach to drug development that includes the gelatinase inhibitor ACT-03. The company addresses the significant medical challenge posed by CNS diseases, which affect 14% of the global population and incur annual costs of $1.5 trillion.

Ate is a food journaling app that utilizes a photo-based logging system and AI-driven insights to help users cultivate mindful eating habits and track their emotional relationship with food. By simplifying the tracking process to just three taps, Ate addresses the challenge of maintaining awareness around food choices without the burden of calorie counting or restrictive diets.

Connecta Therapeutics develops targeted therapies for central nervous system disorders by utilizing advanced translational medicine techniques to address significant gaps in treatment options. The company focuses on creating effective solutions for patients with unmet medical needs, aiming to enhance their quality of life and support their families.

Kiin utilizes virtual reality and neuroscience to create immersive training scenarios that allow employees to experience discrimination and bias from the perspectives of others, fostering empathy and understanding. This approach enhances interpersonal relationships and increases productivity by promoting a more inclusive workplace culture.

Nanobots Therapeutics develops the MotionTx platform, which utilizes nanobot technology to enhance the penetration of therapeutic agents into tissues and improve drug accumulation in target cells. This approach addresses the challenge of insufficient drug delivery in oncology, potentially transforming treatment outcomes for various diseases.